Kunena :: Тема: Posted by Thrasher on 30.11.2016 10:26:36: erlotinib her (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Thrasher on 30.11.2016 10:26:36: erlotinib her

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Thrasher on 30.11.2016 10:26:36: erlotinib her

Страница:
1
2

ТЕМА: Posted by Thrasher on 30.11.2016 10:26:36: erlotinib her

Posted by Thrasher on 30.11.2016 10:26:36: erlotinib her 8 года 4 мес. назад #939

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
This was a randomized, double-blind, placebo-controlled, multi-institutional phase III study of erlotinib plus gemcitabine (EG) vs gemcitabine plus placebo (PG) in patients with incurable advanced or metastatic pancreatic cancer. This multinational trial was conducted by the National Cancer Institute of Canada Clinical Trials Group in collaboration with OSI Pharmaceuticals, Inc.[11]
The metabolism of Erlotinib can be decreased when combined with Isradipine.
Erlotinib hydrochloride Cas.:183319-69-9
gorodznaniy.com/index.php/forum/dobro-po...cientific-discussion
Experimental Drug Tarceva Extends Lung-Cancer Survival
bzpp64.ru/index.php/forum/razdel-predloz...rlotinib-lung-cancer
Conclusion. Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. Afatinib has similar efficacy compared with erlotinib and gefitinib in first-line treatment of tumors harboring EGFR mutations but may be associated with more toxicity, although further studies are needed. Gefitinib deserves consideration for U.S. marketing as a primary treatment for EGFR-mutant NSCLC.
1. Kaj je zdravilo Tarceva in za kaj ga uporabljamo
Erlotinib (Tarceva™) and gefitinib (Iressa™) tablets, kindly provided by Dr. Nisana Namwat (Khon Kaen University, Khon Kaen, Thailand), were crushed and then dissolved in DMSO for in vitro studies. Between 2,000 - 4,000 U-CH 1 cells were plated in 96-well plates in 200 μL of U-CH1 media and treated the following day with vehicle (0.25% DMSO) or various concentrations of erlotinib and gefitinib ranging from 2.5 nM to 25 uM for 48 h. Proliferation assays were performed using the Cell Titer 96® AQueous One Solution Proliferation Assay according to the recommendations of the manufacturer (Promega, Madison, WI) with minor modifications. Briefly, 20 μL of CellTiter96 AQueous One reagent was added to each well after removing 100 μL of media from each well. Plates were incubated for 3-5 hours at 37°C. Absorbance was measured using the Victor 3 microplate reader (Perkin-Elmer, Walthan, MA). Background absorbance (media alone) was subtracted from each treatment absorbance value and percent inhibition calculated based on DMSO control. Experiments were repeated at least three times with a minimum of 5 replicates in each experiment.
Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ERCC1 status may have some predictive value in EGFR wild-type disease, but requires further investigation.
Gatzemeier U, Pluzanska A, Szczesna A et al. (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced NSCLC. J Clin Oncol 22: 619, Abstract 7010 Google Scholar
www.almavet.ru/component/kunena/2-dobro-...-of-tarceva?Itemid=0
Cromwell I, van der Hoek K, Melosky B, Peacock S: Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis. J Thorac Oncol. 2011, 6: 2097-2103. 10.1097/JTO.0b013e31822f657a. View Article PubMed Google Scholar
Home Ricerca Ricerca clinica Nuovi dati su afatinib per carcinoma polmonare a cellule squamose vs erlotinib
www.real-world.pw/forum/raznoe/378-poste...-erlotinib-bula.html
Erlotinib and picropodophyllin (PPP) act together to reduce cell proliferation. MET1 cells were cultured for 48 hours in increasing concentrations of erlotinib (A) or PPP (

as indicated. Cell growth was then assessed using methyl thiazolyl-tetrazolium (MTT) assays. A dose-dependent decrease in the number of viable cells is seen with rising inhibitor concentrations (n = 3 at all time points). MET1 cells (C), MET4 cells (D), SCC12 cells (E), and SCC13 cells (F) were cultured for 48 hours in varying concentrations of erlotinib and PPP as indicated. Cell growth was then assayed with MTT assays. Both erlotinib and PPP demonstrated dose-dependent inhibition of cell growth, and at intermediate concentrations there seemed to be synergistic prevention of cell growth by both inhibitors. Higher concentrations of all inhibitors were also tested but are not shown as they exceeded the maximal responses of the cells to the inhibitors.
The serum concentration of Erlotinib can be increased when it is combined with Haloperidol.
foodtube.net/profiles/blogs/posted-by-bu...30-21-tarceva-liquid
Antacids should be taken at least 4 h before or 2 h after the daily dose of erlotinib
veloboll.ru/index.php/forumkunena/4-osno...t-150-price-in-india
Chest computed tomography scan showing a dramatic response to targeted therapy in a patient with non-small cell lung cancer. (A) Baseline scan showing a left hilar tumor, lymphangitic spread, and a large pleural effusion. (

Follow-up scan after two months of treatment with erlotinib (Tarceva), an oral small molecule inhibitor targeting epidermal growth factor receptor.
Lung adenocarcinomas sensitive to the epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib often harbor somatic mutations in exons encoding the EGFR tyrosine kinase domain. 7,8,13 Nearly 90% of these mutations occur as either multinucleotide in-frame deletions in exon 19 that eliminate four amino acids (LREA), or as single missense mutations that result in substitution of arginine for leucine at position 858 (L858R).
Progression-free survival was also significantly improved with afatinib (average 2.6 months) compared to erlotinib (average 1.9 months). Overall, patients receiving afatinib were 18% more likely to have no signs of disease progression during the study period. Treatment response was observed in 51% of patients receiving afatinib . This was significantly greater than 40% of patients receiving erlotinib .
It is important that you follow the instructions and directions on the tarceva tablets package carefully before using. You must also tell your doctor about any medical conditions that you may have. Also, if you have any allergies or any other problems, tell the doctor before you start taking erlotinib, tarceva 100 mg or tarceva nsclc. There are many side effects of tarceva with lung cancer and your doctor should know about any previous medical conditions.
amceramica.ru/index.php?option=com_kunen...=8&id=21877&Itemid=0
TARCEVA ® en combinación con quimioterapia: Las RAMs listadas en la tabla 5 se basan en la información del brazo de erlotinib de un estudio clínico controlado (PA.3), realizado en 259 pacientes con cáncer pancreático quienes recibieron 100 mg de TARCEVA ® más gemcitabina en comparación con 256 pacientes en el brazo del placebo más gemcitabina.
Pennell NA, Neal JW, Chaft JE, et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol. 2014;32(15 suppl; abstr 7514).